Kinesin motor domain of Leishmania donovani as a future vaccine candidate

Clinical and Vaccine Immunology

Volumn 15, Issue 5, 2008, Pages 836-842

  Dey, Ayan ^a   Sharma, Pawan ^b   Redhu, Naresh Singh ^a,c   Singh, Sarman ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G2; INTERLEUKIN 2; INTERLEUKIN 4; KINESIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; CYTOKINE; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOAL VACCINE; PROTOZOON ANTIBODY; RECOMBINANT VACCINE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE LOCUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREACTIVITY; LEISHMANIA DONOVANI; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; VACCINATION; VISCERAL LEISHMANIASIS; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMISTRY; DISEASE MODEL; GENETICS; IMMUNOLOGY; PROTEIN MOTIF; TH1 CELL;

AMINO ACID MOTIFS; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BLOTTING, WESTERN; CYTOKINES; DISEASE MODELS, ANIMAL; KINESIN; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; TH1 CELLS; VACCINES, SYNTHETIC;

EID: 46249118167     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00433-07     Document Type: Article

References (31)

1. Alarcon, J. B., G. W. Waine, and D. P. McManus. 1999. DNA vaccines: technology and application as anti-parasite and anti-microbial agents. Adv. Parasitol. 42:343-410.
2. Basu, R., S. Bhaumik, J. M. Basu, K. Naskar, T. De, and S. Roy. 2005. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J. Immunol. 174:7160-7171.
3. Burns, J. M., Jr., W. G. Shreffler, D. R. Benson, H. W. Ghalib, R. Badaro, and S. G. Reed. 1993. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral Leishmaniasis. Proc. Natl. Acad. Sci. USA 90:775-779.
4. Carvalho, E. M., R. Badaro, S. G. Reed, T. C. Jones, and W. D. Johnson. 1985. Absence of gamma-interferon and interleukin 2 production during active visceral leishmaniasis. J. Clin. Investig. 76:2066-2069.
5. Cenini, P., N. Berhe, A. Hailu, K. McGinnes, and D. Frommel. 1993. Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J. Infect. Dis. 168:986-993.
6. Chang, K. P., and B. S. McGwire. 2002. Molecular determinants and regulation of Leishmania virulence. Kinetoplastid Biol. Dis. 1:1-7.
7. Cillari, E., F. Y. Liew, P. L. Campo, S. Milano, S. Mansueto, and A. Salerno. 1988. Suppression of IL-2 production by cryopreserved peripheral blood mononuclear cells from patients with active visceral leishmaniasis in Sicily. J. Immunol. 140:2721-2726.
8. Coler, R. N., Y. A. W. Skeiky, K. Bernards, K. Greeson, D. Carter, C. D. Cornellison, F. Modabber, A. Campos-Neto, and S. G. Reed. 2002. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiolspecific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70:4215-4225.
9. + T cells. Infect. Immun. 75:4648-4654.
10. Garg, R., S. K. Gupta, P. Tripathi, S. Naik, S. Sundar, and A. Dube. 2005. Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clin. Exp. Immunol. 140:149-156.
11. Garraud, O., R. Perraut, G. Riveau, and T. B. Nutman. 2003. Class and subclass selection in parasite-specific antibody responses. Trends Parasitol. 19:300-304.
12. Ghalib, H. W., M. R. Piuvezam, Y. A. W. Skeiky, M. Siddiq, F. A. Hashim, A. M. El-Hassan, D. M. Russo, and S. G. Reed. 1993. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J. Clin. Investig. 92:324-329.
13. Ghosh, A., W. W. Zhang, and G. Matlashewski. 2001. Immunization with A2 protein results in mixed Th1/Th2 and a humoral response which protects against Leishmania donovani infections. Vaccine 20:59-66.
14. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glachenhaus, and R. A. Seader. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with L. major. J. Exp. Med. 186:1137-1147.
15. Haldar, J. P., S. Ghose, K. C. Saha, and A. C. Ghose. 1983. Cell-mediated immune response in Indian kala azar and post-kala azar dermal leishmaniasis. Infect. Immun. 42:702-707.
16. Herwaldt, B. L. 1999. Leishmaniasis. Lancet 354:1191-1199.
17. Ho, M., D. K. Koech, D. W. Iha, and A. D. M. Bryceson. 1983. Immunosuppression in Kenyan visceral leishmaniasis. Clin. Exp. Immunol. 51:207-214.
18. Iwai, S., A. Ishiji, I. Mabuchi, and K. A. Sutoh. 2004. Novel actin-bundling kinesin-related protein from Dictyostelium discoideum. J. Biol. Chem. 6:4696-4704.
19. Karp, C. L., S. H. El-Safi, T. A. Wynn, M. M. Satti, A. M. Kordofani, F. A. Hashim, H. A. Mohammed, A. N. Franklin, N. B. Thomas, and D. L. Sacks. 1993. In vivo cytokine profiles in patients with kala-azar: marked elevation of both interleukin-10 and interferon-γ. J. Clin. Investig. 91:1644-1648.
20. Kawano, Y., T. Noma, and J. Yata. 1994. Regulation of human IgG subclass production by cytokines. IFN-gamma and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of IgG2. J. Immunol. 153:4948-4958.
21. Kemp, M., J. A. Kurtzhals, K. Bendtzen, L. K. Poulsen, M. B. Hansen, D. K. Koech, A. Kharazmi, and T. G. Theander. 1993. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect. Immun. 61:1069-1073.
22. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. lmmunol. Methods 65:55-63.
23. Murray, H. W., and C. F. Nathan. 1999. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 189:741-746.
24. Peruhype-Magalhães, V., O. A. Martins-Filho, A. Prata, A. Silva Lde, A. Rabello, A. Teixeira-Carvalho, R. M. Figueiredo, S. F. Guimarães-Carvalho, T. C. Ferrari, and R. Correa-Oliveira. 2005. Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome. Scand. J. Immunol. 62:487-495.
25. Russo, D. M., J. M. Burns, Jr., E. M. Carvalho, R. J. Armitage, K. H. Grabstein, L. L. Button, W. R. Mcmaster, and S. G. Reed. 1991. Human T cell responses to gp63, a surface antigen of Leishmania. J. Immunol. 147:3575-3580.
26. Seder, R. A., and S. Gurunathan. 1999. DNA vaccines: designer vaccines for the 21st century. N. Engl. J. Med. 341:277-278.
27. Singh, H., and G. P. S. Raghava. 2001. ProPred: prediction of HLA-DR binding sites. Bioinformatics 17:1236-1237.
28. Sivakumar, R., P. Sharma, K. P. Chang, and S. Singh. 2006. Cloning, expression and purification of a novel recombinant antigen Leishmania donovani. Protein Expr. Purif. 46:156-165.
29. Stager, S., D. F. Smith, and P. M. Kaye. 2000. Immunization with a recombinant stage regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J. Immunol. 165:7064-7071.
30. Sukumaran, B., P. Tewary, S. Saxena, and R. Madhubala. 2003. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine 21:1292-1299.
31. Zwingenberger, K., G. Harms, C. Pedrosa, S. Omena, B. Sandkamp, and S. K. Neifer. 1990. Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferon-γ production. Clin. Immunol. Immunopathol. 57:242-249.